Rivastigmine transdermal compositions and methods of using the same
US10357463B2 · kind B2 · utility
0Cited by
8References
23Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 9, 2018 |
| Grant date | Jul 23, 2019 |
| Priority date | — |
| Expiry date | Mar 9, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.